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Abstract: Biologic agents have been designed with the help of immunological studies to target 
particular areas of the immune system which are thought to play a role in the pathogenesis of 
disease. Etanercept is a soluble anti-tumor necrosis factor alpha (TNF-α) agent licensed for 
the treatment of active poly-articular juvenile idiopathic arthritis (JIA) in children aged 4 to 
17 years who have failed to respond to methotrexate alone, or who have been intolerant of 
methotrexate. The safety and efﬁ  cacy of etanercept in this patient group has been established by 
one randomized controlled trial and several longitudinal studies. This, together with the fact that 
until recently etanercept was the only anti-TNF licensed in JIA, has made it the most common 
ﬁ  rst choice biologic for many clinicians. However, there are still many unanswered questions 
about etanercept, including its efﬁ  cacy and safety in different subtypes of JIA, in children under 
4 years of age and in those with uveitis. There are still concerns about the long term safety of 
TNF antagonists in the pediatric age group and unanswered questions about increased risks of 
malignancy and infection. Although adult studies are useful to improve understanding of these 
risks, they are not a substitute for good quality pediatric research and follow-up studies. Adult 
trials often include greater numbers of patients. However, they evaluate a different population 
and drug behavior may vary in children due to differences in metabolism, growth and impact 
on a developing immune system. In addition, rheumatoid arthritis is a different disease than 
JIA. Clinicians need to carefully weigh up the risk beneﬁ  t ratio of anti-TNF use in children 
with JIA and push for robust clinical trials to address the questions that remain unanswered. 
This article summarizes the evidence available for use of etanercept in children with JIA and 
highlights aspects of treatment in need of further research.
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Introduction
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of conditions deﬁ  ned as 
inﬂ  ammatory arthritis occurring in those under 16 years of age, present for greater than 
6 weeks, after exclusion of other causes. The revised International League Against 
Rheumatism (ILAR) classiﬁ  cation deﬁ  nes 7 subsets of JIA (Table 1).1 Management 
and treatment response differ between subgroups. Many children respond to tradi-
tional treatments which include a combination of non-steroidal anti-inﬂ  ammatory 
drugs (NSAIDs), corticosteroids (intra-articular, pulsed intravenous, oral) and disease 
modifying anti-rheumatic drugs (DMARDs) of which methotrexate is most commonly 
used.2 In oligo-articular JIA, intra-articular steroid injections alone may be sufﬁ  cient 
to control disease. In most other sub-groups, it has become standard practice to use a 
disease modifying agent (usually methotrexate) at diagnosis. Methotrexate takes 6 to 
8 weeks to start to show an effect. Meanwhile, inﬂ  ammation can be controlled with 
either intra-articular steroids or pulsed methylprednisolone depending on number and 
type of joints affected. The percentage of ‘non-responders’ to methotrexate can be as 
high as 30% or more depending on JIA-subtype.3,4 In 430 children with polyarticular Biologics: Targets & Therapy 2009:3 128
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JIA 72% responded as deﬁ  ned by ACR Pediatric 30 criteria 
but only 12% met the deﬁ  nition of complete disease control.3 
Response rates are lower for children with systemic JIA and 
enthesitis-related arthritis.4 The advent of biologics has been of 
great importance in the management of children with refractory 
JIA who historically have suffered the greatest damage from 
unchecked inﬂ  ammation and treatment side-effects.
Biologics describe a class of drug that has been designed to 
have biologic properties and include monoclonal antibodies, 
soluble cytokine receptors and recombinant receptor 
antagonists.2 This includes drugs that block TNF-α such as 
etanercept, inﬂ  iximab and adalimumab as well as other agents 
such as anakinra, tocilizumab, abatacept and rituximab.
Etanercept is a recombinant fusion protein combining 
two human soluble p75 TNF receptors with an Fc domain 
of human IgG1 which binds TNF-α and α-lymphotoxin 
reducing inﬂ  ammation. It is given as a subcutaneous injection 
twice weekly at a dose of 0.4 mg/kg and is licensed and 
recommended by the Food and Drugs Administration (FDA) 
in USA in children over 2 years, the National Institute for 
Health and Clinical Excellence (NICE) in the UK, and the 
European Agency for the Evaluation of Medicinal Products 
(EMEA) of the EU in children over 4 years with polyar-
ticular JIA unresponsive or intolerant to methotrexate. Until 
recently etanercept has been the only anti-TNF licensed in 
children and this together with its good long term efﬁ  cacy 
and safety proﬁ  le have made it the ﬁ  rst choice anti-TNF 
treatment in most children with JIA that fail methotrexate. 
Adalimumab, another anti-TNF, has recently been licensed 
in several countries and offers an alternative. It is licensed in 
the UK for treatment of JIA in adolescents and in the USA 
for children 4 years and older. Other biologic therapies are 
used off license in certain circumstances.
The pathophysiology of JIA is complex. An imbalance 
between proinﬂ  ammatory and anti-inﬂ  ammatory elements 
of the immune system is described with TNF-α playing an 
Table 1 ILAR Classiﬁ  cation of JIA1
Category Deﬁ  nition
Systemic onset JIA a) Arthritis in 1 or more joints and
b) Fever of at least 2 weeks duration that is documented to be daily (‘quotidian’) and
c) One or more of
  i.  Evanescent erythematous rash
  ii.  Generalized lymph node enlargement
  iii. Hepatomegaly and/or splenomegaly
 iv.  Serositis
Oligoarticular JIA Arthritis affecting 1 to 4 joints during the ﬁ  rst 6 months of disease
Two subgroups:
  1. Persistent oligoarthritis: affecting 4 joints throughout the disease course
  2. Extended oligoarthritis: affecting 4 joints after the ﬁ  rst 6 months
Polyarthritis (RF negative) Arthritis affecting 5 or more joints during the ﬁ  rst 6 months of disease; (RF negative)
Polyarthritis (RF positive) Arthritis affecting 5 or more joints during the ﬁ  rst 6 months of disease;
2 or more tests for RF are positive (at least 3 months apart)
Psoriatic arthritis Arthritis and psoriasis, or arthritis and at least 2 of the following:
 a)  Dactylitis
  b) Nail pitting and onycholysis
  c) Psoriasis in a ﬁ  rst-degree relative
Enthesitis-related arthritis Arthritis and enthesitis, or arthritis or enthesitis with at least 2 of the following:
  a) Sacroiliac joint tenderness and/or inﬂ  ammatory lumbosacral pain
  b) The presence of HLA-B27 antigen
  c) Onset of arthritis in a male over 6 years of age
  d) Acute (symptomatic) anterior uveitis
 e)    History of ankylosing spondylitis, enthesitis-related arthritis, sacroiliitis with inﬂ  ammatory 
bowel disease, Reiter’s syndrome or acute anterior uveitis in a ﬁ  rst-degree relative.
Undifferentiated arthritis Arthritis that fulﬁ  ls criteria in no category or in 2 or more of the above categories.
Abbreviation: RF, rheumatoid factorBiologics: Targets & Therapy 2009:3 129
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important role in driving inﬂ  ammation. This is conﬁ  rmed in 
studies showing signiﬁ  cantly elevated levels of serum and 
synovial ﬂ  uid TNF-α and interleukin (IL)-2, IL-6, interferon 
(IFN)β and IFN-γ as well as high levels of synovial ﬂ  uid IL-
1α with corresponding impaired production of anti-inﬂ  am-
matory cytokines.5,6 Cytokine levels appear to correlate with 
disease activity including soluble TNF receptor levels.7
The morbidity of JIA can be marked and complications 
include pain, disability, deformity, growth failure, 
osteoporosis, macrophage activation syndrome, amyloidosis 
and even death. This affects the child’s education, social 
functioning, psychological well-being and also has affects 
on the family.
Prior to publication of follow-up studies in JIA, there 
was a common viewpoint that JIA would often remit in 
adulthood. These studies challenge this, suggesting that JIA 
has a greater long-term consequence and progresses into 
adulthood more frequently than initially thought.8–12 Only 
patients under regular follow up in adulthood were included 
and thus these studies were biased towards the more severe 
end of the spectrum, excluding those patients with mild or 
resolved disease.
In one study, 42.9% of adults with JIA have severe 
functional limitations as measured by a Health Assessment 
Questionnaire (HAQ) score of 1.5. Those at greatest 
risk were patients with polyarticular disease course and in 
particular systemic JIA. 36.3% were still taking a DMARD 
and 43.3% had clinically active disease. Adults with systemic 
onset JIA had accrued more damage from their disease.11 
Adults with JIA achieved higher academic qualiﬁ  cations than 
their peers but they were more likely to be unemployed.8,10 
21.1% had suffered depression at some point and 31.9% had 
severe pain as measured on a visual analog scale.12
These follow-up studies provide further support to treat 
children with JIA ‘early and aggressively’. A long-term 
follow-up study has demonstrated sustained beneﬁ  ts of early 
disease control. Even after 9 years, patients randomized to 
early sulfasalazine use versus placebo had a better outcome.13 
This has to be balanced with the side-effects of treatments, 
many of which are relatively new and may have a long term 
safety proﬁ  le that is not completely understood.
Efﬁ  cacy of etanercept in JIA
It has become standard practice in therapeutic trials of 
JIA to measure efﬁ  cacy using the American College of 
Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50, Pedi 
70, Pedi 90, and Pedi 100 criteria for improvement based 
on the core set criteria. The core set of 6 responses include 
number of active joints, number of joints with limitation of 
movement, physician’s assessment of disease activity (visual 
analog scale [VAS] 0–10 cm), parental assessment of patient’s 
overall well-being (VAS), validated measure of physical 
function (Child Health Assessment Questionnaire [CHAQ]) 
and a laboratory measure of inﬂ  ammation (Erythrocyte 
Sedimentation Rate, ESR). Definition of improvement 
for ACR Pedi 30 requires at least 30% improvement from 
baseline in at least 3 out of 6 of the core set with no more 
than one of the core set worsening by 30%.14 ACR Pedi 50, 
70, 90 and 100 are improvements from baseline of at least 
50%, 70%, 90% or 100% respectively in at least 3 out of 6 
core criteria and with no more than one of core set worsening 
by 30%. Outcome can also be assessed by radiological 
progression of disease and quality of life data.
The efﬁ  cacy of etanercept in controlling disease activity 
in children with JIA has been demonstrated in one random-
ized control trial (RCT) and several non-randomized trials 
(Table 2). All studies except the initial open label extension 
and RCT used concomitant methotrexate.
In a two stage study, 69 patients aged 4 to 17 years with 
active polyarticular JIA despite treatment with methotrexate 
at 10 mg/m2 entered an open label study where they 
all received subcutaneous etanercept at 0.4 mg/kg twice 
weekly.15 Sixty-four patients (93%) completed treatment of 
3 months. The response rate was 74% (51/69) and was often 
rapid within the ﬁ  rst few weeks of treatment. At the end of 
3 months 64% had an ACR50 response and 36% ACR70 
response.
The responders (n = 51) were eligible for a double-blind 
randomized control trial for 4 months. Signiﬁ  cantly more 
patients ﬂ  ared in the placebo group compared to the etaner-
cept group (81% versus 28%, p = 0.003) and the median time 
to ﬂ  are was signiﬁ  cantly greater in the etanercept versus the 
placebo group (116 days versus 28 days, p  0.001).15
At the end of the RCT 80% (20/25) of patients on 
etanercept achieved ACR30 compared with 35% (9/26) in 
the placebo group. The median improvement in CHAQ was 
54% compared with no obvious change in the placebo group. 
There was no signiﬁ  cant difference in adverse events in the 
treatment group versus placebo.15
Efﬁ  cacy and safety have been shown to continue in 
follow-up studies at 2, 4 and 8 years in 318 patient years 
of exposure.16–18 Children included in this study had severe 
refractory JIA with mean disease duration at recruitment of 
5.9 years. This long disease duration may have resulted in a 
lower efﬁ  cacy of etanercept than if it had been used earlier 
in the disease course.Biologics: Targets & Therapy 2009:3 130
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Although etanercept had good efﬁ  cacy it did not lead to 
drug free remission in the majority of children. With time, 
most went on to receive methotrexate, alternative DMARDs 
or corticosteroids for disease ﬂ  ares. At baseline, no patients 
received DMARDS whilst during 8 years 53% received one 
or more DMARDs (38% being methotrexate). Twenty-nine 
percent of patients received corticosteroids at the beginning 
of the open label extension which increased to 60% at some 
point during 8-year follow up.17
Sixty-six percent of patients withdrew during 8 years with 
the reasons stated as: parent or child refusal 14%, suboptimal 
clinical response 12%, physician decision 9%, adverse events 
7%, lost to follow-up 5%, protocol issues 5% and other reasons 
14%. At 8 years response to treatment (for those still on treat-
ment) was ACR30 83% (40 of 48 patients), ACR50 77% (36 of 
47 patients), ACR70 61% (28 of 46 patients), ACR90 41% 
(19 of 46 patients) and ACR100 18% (8 of 45 patients).17
Subsequent studies have demonstrated similar efﬁ  cacy. 
An observational study of 146 patients with JIA (all sub-
types) in a Dutch registry included 436 patient years of 
exposure. At 3 months of treatment, an ACR 30 was seen 
in 77% of patients. The response was sustained and 36% 
of all patients met remission criteria. 67% of patients at 15 
months had discontinued corticosteroid treatment. One third 
of patients remained on etanercept as a single agent.19
A small study of 21 children with polyarticular and 
systemic JIA showed that starting etanercept had a signiﬁ  cant 
impact on functional status, emotional well being and quality 
of life scores.20
In addition to improving clinical outcomes, a study of 
40 patients with polyarticular JIA included in an Italian 
registry has suggested that etanercept improves radiological 
progression of disease as measured by Poznanski score 
(carpo-metacarpal ratio) at baseline and 1 year.21
Etanercept has been shown to improve growth velocity in 
children with JIA. The most signiﬁ  cant predictor of growth 
rate was the degree of inﬂ  ammation, even after the reduction 
of corticosteroid dose was taken into account suggesting 
that improved growth on etanercept is secondary to reduced 
inﬂ  ammation.22 This was conﬁ  rmed in another study that showed 
signiﬁ  cant increase in height velocity after etanercept was com-
menced in prepubertal children. In pubertal children, height 
increase on etanercept did not reach statistical signiﬁ  cance, but 
this may have been due to an underpowered study.23
Challenges of using etanercept 
in children with JIA
Do all subsets of JIA respond equally 
well to etanercept?
There are a growing number of data available on safety 
and efﬁ  cacy of etanercept for use in polyarticular JIA, but 
results may not be generalizable to all disease sub-types. 
Systemic onset JIA (sJIA), although less common than 
Table 2 Published studies on the use of etanercept in children with JIA; study populations described as polyarticular JIA include all those subtypes 
that had more than 4 joints involved and may include RF positive and RF negative JIA, psoriatic, systemic and enthesitis-related arthritis
Author(s), year Number of patients Study population  Study design
Haapasaari et al 200277 31 Polyarticular JIA Retrospective
Henrickson and Reiff 200437 8 ERA Uncontrolled open label trial
Horneff et al 200852 604 All JIA Prospective observational
Kietz et al 200278 22 Polyarticular JIA Uncontrolled open
Kimura et al 200529 82 Systemic JIA Retrospective questionnaire
Lahdenne et al 200379 10 Polyarticular JIA Uncontrolled, open label
Lovell et al 200015 69 Polyarticular JIA Open label trial
Lovell et al 200015 51 Polyarticular JIA RCT
Lovell et al 200316 43 Polyarticular JIA Uncontrolled extension trial
Lovell et al 200618 34 Polyarticular JIA Uncontrolled extension trial
Lovell et al 200817 26 Polyarticular JIA Uncontrolled extension trial
Prince et al 200819 146 All JIA except persistent oligoarticular Prospective observational
Quartier et al 200330 61 Polyarticular JIA Uncontrolled open label trial
Russo et al 200231 15 Systemic JIA Prospective observational
Schmeling et al 200151 7 All JIA except persistent oligoarticular Case series
Takei et al 200132 8 Polyarticular JIA Retrospective, high dose etanercept
Abbreviations: ERA, enthesitis-related arthritis; RCT, randomized controlled trial; RF, rheumatoid factor.Biologics: Targets & Therapy 2009:3 131
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other sub-groups can be very challenging to treat. Trials 
that include this sub-group tend to select patients that have 
a polyarticular course, but no signiﬁ  cant systemic symptoms 
at time of treatment. There is a paucity of evidence for the 
use of etanercept in other sub-groups such as psoriatic JIA 
and enthesitis-related arthritis.
Etanercept in systemic JIA
Increasing evidence from trial and registry data suggests that 
children with sJIA do not respond as well to etanercept as 
children with polyarticular disease. There are growing data that 
sJIA is driven by other pro-inﬂ  ammatory cytokines other than 
TNF, such as IL-1, IL-6 and IL-18.24–26 Early reports of the use 
of anakinra (1L-1RA)26 and tocilizumab (anti-IL-6 monoclonal 
antibody)27 show promise in this sub-group of JIA.
The RCT of etanercept in JIA showed that patients with 
sJIA had a higher rate of disease ﬂ  are (44%) than other 
subsets.15 A long-term follow up study of the Dutch national 
register demonstrated that patients with sJIA responded less 
well than other subtypes across ACR30, 50 and 70 responses 
(p  0.01) and withdrawal secondary to poor clinical response 
was also more likely (p  0.001).19 Although response to 
etanercept was less predictable in children with sJIA, those 
that did respond showed similar efﬁ  cacy to other groups in the 
long-term, with 38% of all systemic patients entering remis-
sion on etanercept.19 Since this was an observational study, 
patients may have been on other concomitant medications 
that may have made a difference to their outcome.
Other authors have documented similar disappointing 
response rates in this sub-group. An analysis of 322 patients 
with JIA treated with etanercept and monitored within 
the German registry has demonstrated lower therapeutic 
efﬁ  cacy of etanercept in children with sJIA compared to 
other subgroups.28
A retrospective study of 82 patients with active and 
refractory sJIA showed a signiﬁ  cant decrease in active joint 
count, ESR, physician global VAS and the number of patients 
on prednisolone (46% ceasing need for corticosteroids). 
However, 54% had a poor response to etanercept and 
45% had at least one ﬂ  are. 35% of patients discontinued 
etanercept, mostly due to poor response or disease ﬂ  are.29 
This study is limited by the retrospective standardized 
questionnaire methodology and poor response rate. An 
open label, prospective, multi-center study by Quartier et al 
also demonstrated a higher rate of treatment failure in sJIA 
compared to other subgroups.30
In another small observational study of 15 patients with 
refractory sJIA treated with etanercept in combination with 
methotrexate, an initial response was seen, but was only 
sustained in 20% of patients. In others, increasing ﬂ  ares and 
progressive loss of effectiveness was seen over time.31 The 
use of high dose etanercept (0.8 mg/kg/dose) had a beneﬁ  cial 
effect in 2 out of 5 patients with sJIA failing to respond 
to conventional doses.32 Thus, dose modiﬁ  cations may be 
required in patients with active sJIA.
Etanercept is tolerated in this sub-group of JIA with few 
adverse effects. There has been one report of commencement 
of etanercept and the development of macrophage activation 
syndrome in a patient with sJIA.33 Patients with sJIA are at 
risk of developing this complication and it is unlikely that 
etanercept was causal in this case but may represent the 
inability of etanercept to control disease. Also, etanercept 
has been used successfully in the treatment of macrophage 
activation syndrome.34
In order to determine accurate efﬁ  cacy of etanercept 
in sJIA, prospective multi-center RCTs are needed using 
validated response criteria for sJIA that could incorporate 
other features of disease as well as joint count and core set, 
such as fever, rash, anemia, pericarditis, or macrophage 
activation syndrome. Current JIA research or registry data do 
not often capture systemic features such as rash or fever.
Etanercept and enthesitis-related 
arthritis (ERA)
Adult data of patients with ankylosing spondylitis have 
shown etanercept to be efﬁ  cacious and well tolerated in 
several RCTs.35,36
Pediatric data are limited to uncontrolled studies, but 
suggest that etanercept may be efﬁ  cacious for children with 
ERA. In a pilot study of 8 patients with active ERA, all had 
improvement in active joint count. Four out of the 8 patients 
had enthesitis which completely resolved on treatment. This 
clinical improvement was sustained over a 2-year follow-up 
period.37 A further case report showed rapid and sustained 
clinical improvement, with radiological remission at 2 years 
demonstrated by magnetic resonance imaging.38
Extended oligoarticular JIA
Extended oligoarthritis can be associated with a worse 
prognosis compared to other sub-groups of disease and 
early aggressive treatment is warranted.39 An observational 
study of 61 patients looking at efﬁ  cacy of etanercept in dif-
ferent sub-groups of JIA indicated similar response rates in 
extended oligoarticular and polyarticular subgroups.30 Other 
studies have included children with extended oligoarticular 
JIA and have shown good efﬁ  cacy to etanercept.19Biologics: Targets & Therapy 2009:3 132
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Etanercept and psoriatic arthritis
Etanercept has been shown to be efﬁ  cacious in adult patients 
with psoriatic arthritis with improvement of skin and joint 
symptoms and slowed radiographic progression.40 Trials 
in children with psoriatic JIA are lacking. Data from the 
German biologics registry of 11 children with psoriatic JIA 
showed the response rate to etanercept was comparable with 
polyarticular JIA with more than 80% reaching ACR Pedi 
30 response versus ACR Pedi 30 response of in those with 
polyarticular JIA.41 These rates were also observed in the 
Dutch registry in 8 patients.19
Uveitis
The risk of developing uveitis in children with JIA is 
approximately 10% to 25%. Twenty-four percent of 
JIA patients who develop uveitis will develop ocular 
complications, of which cataracts is the most common.42 
Topical corticosteroids remain ﬁ  rst line treatment, followed 
by addition of DMARDs such as methotrexate, ciclosporin 
A or mycophenolate mofetil, progressing to anti-TNF therapy 
for resistant disease.
Trials of etanercept versus placebo show conﬂ  icting 
results. An underpowered double blind RCT of 12 patients 
did not detect any difference in ocular inﬂ  ammation between 
placebo and etanercept43 and a retrospective study showed 
no signiﬁ  cant change in number of ﬂ  ares of uveitis before 
or after etanercept therapy.44 However, a small prospective 
study showed a statistically signiﬁ  cant improvement in 10/16 
eyes (63%) with improvements in visual acuity in 40%. Those 
who did not initially respond showed no improvement with 
an increased dose of etanercept.45
In a small non-randomized trial of patients with refractory 
JIA started on anti-TNFs, patients on inﬂ  iximab had greater 
reduction in inﬂ  ammatory activity of uveitis compared to 
those treated with etanercept (p = 0.047) and experienced 
less ﬂ  ares of uveitis (p = 0.015). 5/24 patients on etanercept 
developed new onset uveitis.46 In patients with refractory 
uveitis, 32% had no response to etanercept as measured 
by 50% reduction in oral and topical corticosteroids, 
whereas all patients in the inﬂ  iximab group showed 50% 
reduction in oral or topical corticosteroids, reaching statistical 
signiﬁ  cance. 35% of patients on etanercept were changed 
on to inﬂ  iximab and a response was noted. Three patients 
who did not respond to inﬂ  iximab had a good response to 
adalimumab. The mean time of duration of uveitis before 
starting anti-TNF treatment was 52 months.47
Children who show a poor response to one agent may 
beneﬁ  t from change to another anti-TNF. Currently, treatment 
of JIA associated uveitis with anti-TNF therapy is reserved 
for those with resistant disease and response may be greater 
in a population with lower duration of inﬂ  ammation and less 
damage from uveitis and treatment. The efﬁ  cacy of etanercept 
in patients with JIA associated uveitis is yet to be determined 
and requires robust randomized, placebo control trials or 
head to head trials with other anti-TNFs. Meanwhile, small 
studies suggest that inﬂ  iximab and potentially adalimumab 
have better efﬁ  cacy in this group.
Under 4 years of age
Etanercept is licensed for use in children with JIA who are 
over the age of 4 in Europe and the UK, while in the US it 
is licensed in children over 2 years of age. There is only one 
observational study that looks at etanercept efﬁ  cacy and safety 
in children below the age of 4 years. Twenty-ﬁ  ve children 
with JIA were identiﬁ  ed from the German registry. There 
were no serious adverse events (SAE) identiﬁ  ed. The authors 
compared data with those from older children and found 
no major differences in safety or efﬁ  cacy despite a higher 
proportion of children less than 4 years of age having sJIA, 
higher disease activity and more frequent corticosteroid and 
methotrexate use at baseline.17,48 The authors conclude that the 
cut off of 4 years is artiﬁ  cial with no clear medical basis.
What to do when etanercept fails?
The effect of etanercept is often seen within 2 weeks, although 
full response takes longer to achieve. If a signiﬁ  cant effect is 
not seen within 3 to 4 months, then the patient is considered to 
be a non-responder to the treatment at that dose. When etan-
ercept does not adequately control disease there are several 
options available including using combination therapy 
(etanercept and methotrexate), optimizing conventional 
treatments (changing methotrexate to sub-cutaneous admin-
istration or increasing dose), maximizing etanercept dose or 
changing to an alternative biologic therapy.
Combination therapy
Studies in adult patients with rheumatoid arthritis (RA) 
have shown an increased response rate in those treated 
with combination therapy of etanercept and methotrexate 
compared to etanercept alone.49,50 A pilot study in children 
with refractory JIA showed combination therapy appeared to 
be tolerable and may enhance efﬁ  cacy.51 Another prospective 
study in children with JIA included 504 patients on combina-
tion therapy and 100 patients on etanercept alone. There was 
no signiﬁ  cant difference in discontinuation rates in the two 
groups, suggesting similar tolerability. There was signiﬁ  cant Biologics: Targets & Therapy 2009:3 133
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difference in response rates at 1 year with an ACR30 of 70% 
in etanercept and 81% in combination group (p  0.05) and 
an ACR70 of 45% versus 62% respectively (p  0.01). There 
was no signiﬁ  cant difference in the number of AE reported 
between the two groups. Infectious SAE were more frequent 
in the combination group but this did not reach statistical 
signiﬁ  cance. On subgroup analysis, patients with RF negative 
polyarticular JIA had a signiﬁ  cantly higher response to 
combination therapy versus monotherapy but no statistically 
signiﬁ  cant difference was observed in systemic or psoriatic 
arthritis subgroups. There were important differences in the 
two groups at baseline with the combination group having a 
signiﬁ  cantly higher proportion of RF positive polyarticular 
disease, less enthesitis-related disease and more corticoste-
roid use than the single agent group.52
High dose etanercept
In patients who have had an inadequate response to etanercept 
at 0.4 mg/kg, the dose can be doubled to 0.8 mg/kg/dose 
(to a maximum of 25 mg). Small studies evaluating this 
have not documented a deﬁ  nite improvement. In a study 
of 8 patients with active polyarticular disease unresponsive 
to at least 3 months of standard dose treatment, etanercept 
was increased to at least 0.8 mg/kg/dose. Only 2 out of 
8 patients showed a clinical response but 5 out of 8 patients 
had systemic JIA which may not respond as well to etanercept 
as other JIA subtypes.32 In another study, 7 out of 15 (47%) 
patients with sJIA discontinued etanercept due to lack of 
response even after increasing dose to 1 mg/kg/dose.31
There does not appear to be any increase in AE at high 
dose.29 High dose etanercept appears to be well tolerated but 
may not lead to an increase in efﬁ  cacy.
Once-weekly etanercept
A prospective pilot study of 12 patients showed no change in 
efﬁ  cacy in those changed to once weekly administration of 
etanercept at 0.8 mg/kg/dose. 83% responded to etanercept 
with an ACR30 score and 50% achieved ACR70. Eighty-three 
percent were on concomitant methotrexate. No SAE or serious 
infections were noted.53 A study of 11 patients in remission 
changed to once-weekly dose of 0.8 mg/kg and 2 patients 
initiated on 0.8 mg/kg once weekly showed that this dosing 
regime retained and induced remission in the short term.54
In children who ﬁ  nd it difﬁ  cult to adhere to twice weekly 
injections this pilot suggests a similar efﬁ  cacy and safety 
proﬁ  le to twice weekly administration. Pharmacokinetic 
models in children with JIA showed similar proﬁ  les for once 
weekly versus twice weekly etanercept.55
Safety of etanercept in JIA
In the initial RCT of etanercept there was no signiﬁ  cant 
difference between the rates of adverse events in the etanercept 
versus the placebo group. The most frequent adverse events 
were injection site reactions (39%), upper respiratory tract 
infections (35%), headaches (20%), abdominal pain (16%), 
vomiting (14%), nausea (12%) and rash (10%).15
A recent 8-year open label extension trial of etanercept 
collected 318 patient years of exposure. 23% of the original 
RCT reported SAE representing 0.12 SAE per patient year. 
Reassuringly, there was no increase in the rate of SAE with 
time. Only 7% of patients discontinued etanercept because 
of adverse events. No cases of systemic lupus erythematosis 
(SLE), demyelination, tuberculosis (TB), opportunistic infec-
tion, malignancy or death were identiﬁ  ed.17
In a longitudinal study, SAE were 0.029 per patient 
year with no difference in SAE between subgroups of JIA. 
4% of patients discontinued etanercept because of SAE.19 
Another study showed no difference in rate of SAE between 
subgroups but 20% discontinued etanercept due to SAE.30
Injection site reactions
Injection site reactions are common (28%–39%) but do not 
usually cause cessation of the drug.15,30 They may be an example 
of a T-lymphocyte mediated delayed-type hypersensitivity 
reaction and become less frequent over time due to eventual 
induction of tolerance.56 They do not tend to need any inter-
vention but if symptomatic, they can be helped by application 
of ice or cold compresses, or use of topical corticosteroid or 
antihistamine to the injection site post injection.
Infections
Anti-TNF therapies have been associated with serious 
manifestations of common bacterial infections (such as skin 
abscesses and cellulitis) as well as atypical or opportunistic 
infections such as TB, coccidiomycosis, listeriosis, 
histoplasmosis and aspergillosis.57 In pediatric patients with 
JIA treated with etanercept the overall infection rate was 
22.8%, of which 32 were minor infections and 2 serious 
infections (prosthetic hip infection and bacterial pneumonia).58 
Lovell et al reported 9 cases of medically important infections 
(MMIs) in 8 patients over 8 years (exposure adjusted rate 
0.03 events per patient year). These included pyelonephritis, 
peritonitis and appendicitis, aseptic meningitis secondary to 
varicella, acute varicella infection, soft tissue infection, post-
operative wound infection, sepsis requiring foot amputation, 
dental abscess and gastrointestinal infection. There was no 
increase in the rate of MMIs with time.17Biologics: Targets & Therapy 2009:3 134
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Data from the UK biologics registry in adults with RA 
showed that patients on etanercept had a lower rate of seri-
ous lower respiratory tract infections than inﬂ  iximab and 
adalimumab-treated patients.59
Reactivation of TB is a serious risk in patients commenced 
on anti-TNFs; therefore local guidelines for TB screening 
should be followed. Patients on anti-TNFs have impaired 
granuloma formation allowing mycobacterium spread. In 
such patients TB infection is frequently extrapulmonary or 
disseminated. The risk of TB with anti-TNFs appears to be 
higher in those treated with inﬂ  iximab than etanercept and 
this in part may be explained by the difference in apoptotic 
properties between the two drugs. Adults patients with RA 
developed TB earlier on inﬂ  iximab (median time 3 months) 
than on etanercept (median time 11.5 months).57 However, 
only one case of TB has been reported in children with JIA 
and that child received inﬂ  iximab after etanercept therapy.19
Varicella infection can be more severe in children on 
DMARDs. In the studies of children on etanercept for JIA, 
4 children developed varicella in 258 patient treatment-years. 
Of these, 3 stopped etanercept temporarily and one continued. 
There were no complications.58 During an extension study 
3 children were hospitalized due to varicella.16
Prior to starting anti-TNF treatment children should be 
screened for TB as per local/national guidelines and have 
their varicella and measles immunity checked. In children 
who are non-immune, vaccination is recommended if not 
contraindicated by other DMARD use and if clinical status 
allows delay in starting anti-TNF treatment. In non-immune 
children who can not be vaccinated, parents should be advised 
about what action to take if their child comes into contact 
with varicella.
Autoimmune disease and autoantibodies
Etanercept use in JIA has been linked with the development 
of autoantibodies and rarely with clinical manifestations of 
systemic lupus erythematosis (SLE).60, 61 There have also been 
reports of the development of sarcoid, inﬂ  ammatory bowel 
disease, demyelination and uveitis while on etanercept.19,58,62
The difﬁ  culties with interpretation of these studies is 
identifying whether there is a true causal link between 
anti-TNFs and autoimmune disease rather than association 
only. In published studies, baseline autoantibody status may 
not be stated and it may not be clear whether patients had 
symptoms of autoimmune disease prior to commencing anti-
TNFs. However, if symptoms resolve on ceasing the drug 
and return on re-challenge this provides a strong suggestion 
of causality.
Clinicians should remain vigilant for clinical evidence 
of emerging new autoimmune disease and check laboratory 
titres of autoantibodies if concerned. In the event of clinically 
signiﬁ  cant disease, etanercept may need to be discontinued.
A prospective study of 26 patients with JIA on anti-TNF 
agents for at least 2 years found that 23% developed persistently 
raised autoantibodies. Of those patients on etanercept (n = 14), 
half had positive anti-nuclear antibody (ANA) at baseline and 
5 developed new autoantibodies. Four patients developed 
anti-R1 antibodies and 1 patient developed anti-thyroid anti-
bodies associated with Hashimoto’s thyroiditis (etanercept was 
withdrawn and treatment with thyroxine was ceased 6 months 
afterwards). There was no other link with development of new 
autoantibodies or change in autoantibody titers with clinical 
disease or ﬂ  ares of arthritis.61 This is conﬁ  rmed by Lovell et al 
where autoantibody status in 43 children showed that no child 
who was ANA negative initially became consistently positive, 
and none developed anti-double stranded (ds-DNA) or 
antiphospholipid antibodies.16 However 2 patients (1.6%) on 
etanercept developed anti-dsDNA without clinical sequalae 
in a subsequent study.58
There have been two reports of the development of SLE 
in children with JIA treated with etanercept. A child who 
was previously ANA positive 1:160 and dsDNA negative 
commenced etanercept therapy with a rise in ANA titers to 
1:2560. He developed temperature, urticaria and swollen 
hands with anti-dsDNA becoming 1:320. Etanercept was 
withdrawn but symptoms did not resolve until corticosteroids 
were commenced. These were weaned within a couple of 
months.63 Another patient developed SLE while on etanercept 
manifest as positive anti-dsDNA antibodies, fatigue, hair 
loss, type IV glomerulonephritis and severe lung disease. Her 
disease was not reversible on withdrawing etanercept.60
A review of autoimmune disease induced by anti-TNFs 
identiﬁ  ed 37 reported cases of lupus in adults treated with 
etanercept. Many had clinical features of drug induced 
lupus rather than systemic lupus erythematosis with positive 
autoantibodies and constitutional, cutaneous and musculo-
skeletal symptoms only. Etanercept was withdrawn in 94% 
and 36/37 showed improvement. However, some required 
treatment with steroids and/or other DMARDs. Of note 
80% of patients had RA and some had pre-existing features 
of lupus, suggesting an overlap syndrome. The authors 
conclude that etanercept may cause drug-induced lupus or 
trigger underlying SLE.64
The same review identiﬁ  ed 59 cases of vasculitis in adult 
patients on etanercept, 89% were cutaneous but 29% had 
organ involvement.64Biologics: Targets & Therapy 2009:3 135
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Two out of 146 patients developed sarcoid on etanercept19 
and a single case of new onset diabetes mellitus type 1 after 
5 months of etanercept therapy has been reported.65
Overall, the incidence of auto-antibody formation seems 
to occur less frequently in children compared to adults61 and 
therefore it may follow that the development of autoimmune 
disease may also be less.
Neuropsychiatric
Neuropsychiatric side effects were not recognized in the 
initial trial but with adverse event reporting via national 
registries these have been increasingly identiﬁ  ed. An Italian 
study reported the frequency of neuropsychiatric adverse 
events at 28.1% and included headaches, anxiety, depression, 
aggression, pain amplification syndromes, fatigue and 
vertigo. Severe headache, aggression and pain ampliﬁ  cation 
syndromes appeared to be dose dependent, occurring only 
when etanercept dose was increased above 0.4 mg/kg and 
remitting on return to lower dose. Also reported was a case 
of hypoglossal paralysis without suggestion of demyelination 
or vasculitis on MRI imaging. All neuropsychiatric 
manifestations resolved on stopping or reducing etanercept 
although some required treatment with drugs.58 The frequency 
of severe psychiatric disorder in another study was 2/61.30 
However, these data come from open label trials and therefore 
can not provide information on the incidence of neuropsychi-
atric symptoms in etanercept compared to a control group.
Etanercept and inﬂ  ammatory 
bowel disease
Inﬂ  iximab has been shown to be effective in the treatment 
of Crohn’s disease whilst etanercept has not.66 Inﬂ  iximab is 
a chimeric human murine monoclonal antibody to TNF-α. 
Both etanercept and inﬂ  iximab bind soluble TNF-α but 
only inﬂ  iximab binds to membrane bound TNF. Binding 
of inﬂ  iximab to activated lamina propria T cells induces 
apoptosis. These differences may help to explain why 
inﬂ  iximab is a successful treatment for inﬂ  ammatory bowel 
disease (IBD) while etanercept is not. In fact, etanercept has 
been associated with the development of new-onset IBD.
Of JIA patients on etanercept, 3.9% (n = 5) developed 
new onset inﬂ  ammatory bowel disease.58 Three had biopsies 
which conﬁ  rmed IBD and the other two had symptoms that 
resolved rapidly on cessation of etanercept. All had long 
standing JIA with no previous bowel symptoms to suggest 
arthritis secondary to IBD although IBD-related arthritis 
may present prior to bowel symptoms. All bowel symptoms 
responded to a change of treatment to inﬂ  iximab.58 This is 
conﬁ  rmed in other data sets where 2 patients out of 146 (1%) 
developed IBD19 and 1/61 developed bloody diarrhea and 
abdominal pain on etanercept.30 In 2 cases symptoms stopped 
on withdrawal of treatment and returned with reintroduction 
of etanercept. Both patients had histological conﬁ  rmation of 
Crohn’s disease.30,67 These ﬁ  ndings need to be conﬁ  rmed in 
larger trials but show the importance of registries in detecting 
rarer adverse events associated with etanercept which were 
not discovered in original studies.
Demyelination
On review of the FDA Adverse Events Reporting System, 
17 patients who received etanercept for inflammatory 
arthropathies developed features in keeping with demyelin-
ation with the majority having associated MRI ﬁ  ndings. 
Symptoms included, most commonly, paresthesia, visual 
disturbance due to optic neuritis, confusion, gait disturbance, 
facial palsy and Guillain-Barré syndrome. All events were 
temporally related to etanercept and all improved or resolved 
on withdrawal of etanercept. One patient had a relapse 
of neurological symptoms on restarting etanercept. Two 
patients had JIA but were age 21 at onset of symptoms (1 had 
paresthesia with cervical myelitis on MRI, the other had optic 
neuritis conﬁ  rmed on MRI).62
On open label extension of the initial Lovell study, 
with 318 patient years of exposure, there were no cases of 
demyelination.17 Likewise, no cases were identiﬁ  ed within 
the Dutch registry with 436 years of exposure.19 The German 
registry had 1 suspected case of demyelination out of 610 
patients.52
Tumors
There have been a few case reports of malignancy in 
children treated with etanercept. So far, long term data 
suggest that there is no increase in incidence in tumors 
over time, but the question of malignancy risk in children 
on etanercept remains unanswered and needs close ongo-
ing observation. It is very difﬁ  cult to study the malignancy 
risk in this group as there are no appropriate reference 
groups for comparison to children on etanercept and effects 
of anti-TNFs may only become apparent in longer term 
studies. Importantly, US studies of 318 patient years of 
exposure and Dutch registry data with 436 patient years 
of exposure both identiﬁ  ed no cases of malignancy.17,19 
Data from the German JIA registry identiﬁ  ed 3 malignant 
tumors (yolk sac tumor after 3 weeks of treatment, thyroid 
carcinoma in a 17 year old treated with etanercept for 
10 months and non-Hodgkin’s lymphoma in a patient also Biologics: Targets & Therapy 2009:3 136
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on methotrexate, azathioprine and ciclosporin A).52 In data 
including 258 patient treatment-years, there was one case 
report of a 25-year-old female with long-standing RF posi-
tive polyarticular disease who had also received multiple 
other DMARDS (including methotrexate and inﬂ  iximab) 
developing thyroid cancer whilst on etanercept.58
Worldwide safety data collected on all patients who 
have received anti-TNFs identiﬁ  ed 39 cases of leukemia 
associated with etanercept but the majority of these patients 
were adults with RA, where RA is known to be a risk factor 
for hematological malignancy.68 Adult data of patients with 
RA on anti-TNFs in 89,710 person-years of observation 
found no increased risk of lymphoma compared to patients 
not treated with anti-TNF therapy.69
Other adverse events
A case report of a patient with polyarticular JIA on 
methotrexate and etanercept is described who developed 
thymic enlargement, cervical and hilar lymphadenopathy 
with left sided pleural effusion. Biopsy excluded malignancy 
and confirmed true thymic hyperplasia. Infection was 
also excluded. Clinical features resolved on stopping 
etanercept and methotrexate although methotrexate was 
later restarted.70
Death
On literature review only 3 reports of deaths in patients with 
JIA on etanercept could be identiﬁ  ed. All were patients with 
systemic disease who received multiple immunosuppressive 
agents and had uncontrolled disease despite etanercept. 
Etanercept had not been used for at least 8 months. One 
patient also received inﬂ  iximab and died from TB, one had 
suspected sepsis and one died from macrophage activation 
syndrome.19
Challenges for the future
Despite increasing data on the use of etanercept in JIA and 
adult RA there remain several unanswered questions.
Which biologic therapy should 
be used in which JIA sub-group?
Currently, etanercept tends to be the ﬁ  rst choice biologic 
for treatment of resistant disease in most sub-groups of 
JIA. Although good efﬁ  cacy is demonstrated in polyar-
ticular JIA, there are currently insufﬁ  cient data on other 
sub-groups and head to head trials of different biologics are 
lacking. Preliminary studies suggest that etanercept is less 
efﬁ  cacious than other biologics in systemic onset JIA and 
in uveitis. It also has limited efﬁ  cacy in Crohn’s disease, 
sarcoid, and Wegener’s granulomatosis. Differences can 
perhaps be explained by different drug characteristics, 
binding properties, pharmacokinetics, dosing patterns, and 
possibly by pathophysiology of disease type. Etanercept 
(but not inﬂ  iximab) is known to bind lymphotoxin which is 
important in JIA, immune defence and immune development. 
On the other hand, bolus administration of inﬂ  iximab leads 
to a greater variability of drug concentration over time, but 
better tissue penetration at higher peaks.71 This increased 
penetration may explain why inﬂ  iximab seems to be better 
than etanercept in the control of uveitis, Crohn’s disease and 
vasculitis, although further studies are needed.
At present, we are unable to predict accurately which child 
will respond to any particular biologic. Perhaps this will change 
in the future with a better understanding of genetic and cytokine 
proﬁ  les for different sub-groups. For example, work on sJIA 
has suggested that although TNF-α levels are raised, they are 
out of phase with the fever. In contrast, IL-1α . and IL-6 may 
be more important in the pathogenesis of sJIA.72 Early studies 
suggest a good response to IL-1α blockade with anakinra26 and 
IL-6 blockade with tocilizumab.27 In contrast, patients with 
polyarticular JIA respond less well to anakinra.73
Is there beneﬁ  t in changing biologic 
if anti-TNF therapy fails?
There is evidence to suggest that switching from one anti-
TNF to another is a reasonable therapeutic option in children 
with JIA.74 In addition, therapeutic trials of newer biologics, 
such as abatacept, are including children with JIA who have 
failed anti-TNF therapies.75 This raises questions regarding 
safety of treating children with consecutive biologics and 
drug wash-out times, particularly with use of biologic agents 
such as rituximab that can cause B cell depletion for months 
or even years.
It is not known whether the use of multiple biologics 
over time leads to a cumulative risk of immune modulation, 
malignancy or other events in later life. This is particularly 
important in children who are exposed to biologic therapies 
in their early years and may be at risk of yet unknown 
consequences. However, these potential risks need to be 
balanced against the known risk of disability and damage 
from uncontrolled disease.
Use of multiple biologics has long-term funding implica-
tions. Economic analysis needs to balance use of biologic 
therapies with the cost of long-term disability and morbidity 
including funding for joint replacement surgery, inability to 
work, loss of income and payment of disability beneﬁ  ts.Biologics: Targets & Therapy 2009:3 137
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How long should children with JIA 
remain on biologic therapy?
At present there are few data on withdrawal of drug therapy in 
JIA. Most clinicians continue to treat a child until they have 
had at least 1 year symptom-free period before trying to stop 
a DMARD or biologic. It is unclear whether it is beneﬁ  cial 
to reduce dose or frequency of drug administration gradually 
rather than simply stopping biologic therapy. Data from the 
Dutch registry of 17 patients who discontinued etanercept 
due to good response showed that 53% (n = 9) did not ﬂ  are 
(mean follow up 1.4 years) and that these patients were in 
remission longer before stopping therapy than those that 
did ﬂ  are (1.9 versus 0.3 years; p  0.01). All children that 
ceased etanercept immediately (n = 3) ﬂ  ared. The rest tapered 
their dose before stopping.76 Studies are needed to evaluate 
further when and how to stop biologics and what proportion 
of children will ﬂ  are on cessation.
Should etanercept be used for refractory 
disease or at start of treatment?
Currently, use of etanercept and other biologics is reserved for 
refractory JIA unresponsive to methotrexate or for children 
who fail to tolerate methotrexate. It can be hypothesized that 
disease remission may be achieved earlier by aggressive use of 
a combination of steroid, methotrexate and etanercept at diag-
nosis of JIA, but there is no evidence to conﬁ  rm this. In order 
to answer this question, recruitment is currently taking place in 
the US for a randomized double blind placebo controlled trial of 
early aggressive therapy in polyarticular JIA (TREAT in JIA) 
comparing weekly subcutaneous methotrexate, oral predniso-
lone and once weekly etanercept 0.8 mg/kg with methotrexate, 
oral prednisolone and placebo etanercept at onset of disease 
(http://clinicaltrials.gov/ct2/show/record/NCT00443430).
Are biologic therapies safe in children?
Initial studies in adults and children suggest that etanercept 
and other biologics are efﬁ  cacious and safe in the treatment 
of arthritis. However, with increasing use, potential risks and 
associations are being identiﬁ  ed that were not apparent in initial 
trials. Registries are extremely important to determine safety 
of drug use over time, particularly in children. One current 
difﬁ  culty that needs to be overcome is how to deal with long-
term monitoring when children transfer to adult care since up 
to now separate registries have been kept for JIA and RA.
Conclusions
The available evidence suggests that etanercept is a safe and 
efﬁ  cacious drug for the treatment of JIA. It is generally well 
tolerated with a small proportion of serious adverse events 
and medically important infections. When using etanercept 
or other biologics, it is important to consider other factors that 
may contribute to adverse events, infections and malignancy 
such as longstanding inﬂ  ammatory disease, co-morbidities 
and the frequent use of concomitant DMARDs. Current safety 
data are taken from randomized controlled trials and longi-
tudinal observational studies that include a cohort of patients 
with longstanding refractory disease that may be more prone 
to adverse events from the nature of their disease. In recent 
years, there has been a tendency to treat patients more aggres-
sively earlier in their disease course. It may be by doing this 
that patients are at less risk of adverse events and are able to 
achieve disease remission within a shorter time scale. On the 
other hand, resistant cases may be exposed to cumulative risks 
from the use of multiple biologic therapies over time. The long 
term safety proﬁ  le remains unclear, particularly in relation 
to serious adverse events such as malignancy, infection and 
demyelination in a pediatric age group who may have long 
exposure to anti-TNF therapy from a very early age. Continued 
careful documentation of adverse events within registries is 
crucial, with a remit to follow children into late adulthood.
Published studies looking at the impact of juvenile 
idiopathic arthritis in adult life include patients who were 
treated as children before the advent of biologics. Hopefully, the 
outlook for future populations of JIA patients will be better.
Despite an increasing evidence base for the use of 
etanercept and other biologics in JIA, there are still 
unanswered questions. Further trials are needed and head 
to head trials comparing biologics in different sub-groups 
of disease would be beneﬁ  cial. National and international 
collaboration is necessary to achieve sufficient patient 
numbers to make trials meaningful, particularly for sub-group 
analysis. Over time, a greater insight into the genetic and 
cytokine variability of different JIA sub-groups may lead to 
a better understanding of treatment response and enable more 
targeted treatment for individuals. Meanwhile, etanercept 
has become an established and dependable treatment for 
methotrexate-resistant JIA.
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